Skip to content
  • Brazil
  • Canada
  • Europe
  • India
  • Italy
  • Japan
  • Korea
  • Latam
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
  • Country/Region
  • No block ID is set

  • Clinic Portal
    • +0034963905310
  • Request Information
  • +34 96 390 53 10
  • Part of brands: |
InternationalInternational
  • Country/Region
  • Part of brands: |
  • Patient Journey
    • Before Pregnancy
    • IVF Process
    • Healthy pregnancy
    • After birth
  • Reproductive Health
    • Specialists
      • ERA
      • ERA insight Hub
      • ALICE
      • EMMA
      • EndomeTRIO
      • Infertility Panels
      • EMBRACE
      • PGT-A
      • PGT-A Plus
      • PGT-M
      • PGT-SR
      • CGT
      • NACE
      • Zenit
      • POC Portfolio
      • SAT
      • Newborn Screening
  • Diagnostics
  • About us
    • Igenomix Research
    • About Igenomix
    • Igenomix Worldwide
  • Academy
  • Blog
Genomics Precision Diagnostic > Neurology Precision Panel > Amyloidosis and Neuropathies Precision Panel

Amyloidosis and Neuropathies Precision Panel

Amyloidosis is the general term used to refer to the extracellular tissue deposition of fibrils composed of low molecular weight subunits of a variety of proteins – amyloid proteins. Many of these proteins are normal constituents of serum, but after undergoing conformational changes, their properties change, turning them into insoluble polymers. 
Overview
Indication
Clinical Utility
Genes & Diseases
Methodology
References

Overview

  • Amyloidosis is the general term used to refer to the extracellular tissue deposition of fibrils composed of low molecular weight subunits of a variety of proteins – amyloid proteins. Many of these proteins are normal constituents of serum, but after undergoing conformational changes, their properties change, turning them into insoluble polymers. These polymers accumulate in different systems leading to a plethora of symptoms involving many organs. There are several major forms of amyloidosis depending on the protein which originates the subunit, being AL (Immunoglobulin Light Chain) and AA (Serum Amyloid A Protein) the main types. The predominant mode of inheritance is autosomal dominant.  Neuropathy is a term that refers to a generalized and homogeneous process affecting many peripheral nerves, the distal nerves usually affected most prominently. It has a wide variety of causes, such as diabetes mellitus, alcohol abuse or Charcot-Marie-Tooth Disease. The most relevant manifestations are numbness or tingling in hands and feet, muscle weakness, pain hypersensitivity and loss of balance. The mode of inheritance varies from autosomal dominant to recessive.  

  • The Igenomix Amyloidosis and Neuropathies Precision Panel can serve as an accurate and directed diagnostic tool ultimately leading to a better management and prognosis of the disease. It provides a comprehensive analysis of the genes involved in this disease using next-generation sequencing (NGS) to fully understand the spectrum of relevant genes involved. 

Indication

  • The Igenomix Amyloidosis and Neuropathies Precision Panel is indicated for those patients with a clinical diagnosis or suspicion presenting with or without the following manifestations: 
    • Renal Disease: hematuria (blood in urine) 
    • Cardiomyopathy: chest pain, arrythmia, heart failure 
    • Gastrointestinal Disease: hepatomegaly, bleeding, malabsorption. 
    • Neurologic Abnormalities: dementia, cortical bleeding. 
    • Musculoskeletal Disease: pseudohypertrophy, macroglossia. 
    • Hematologic Abnormalities: anemia, thrombocytopenia. 
    • Pulmonary Disease: dysphagia, Sjögren’s syndrome. 
    • Skin Manifestations: subcutaneous nodules, waxy thickening. 
    • Pain Hypersensitivity 

Clinical Utility

The clinical utility of this panel is: 

  • The genetic and molecular confirmation for an accurate clinical diagnosis of a symptomatic patient.  
  • Early initiation of multidisciplinary treatment in the form of pharmacologic treatment to help reduce the production of insoluble polymers, or even surgical procedures to transplant the affected organ. 
  • Risk assessment and genetic counselling of asymptomatic family members according to the mode of inheritance. 
  • Improvement of delineation of genotype-phenotype correlation. 

Genes & Diseases

Methodology

References

See scientific referrals

Kyle RA, Bayrd ED. Amyloidosis: review of 236 cases. Medicine. 1975 Jul;54(4):271-299. 

Shah KB, Inoue Y, Mehra MR. Amyloidosis and the Heart: A Comprehensive Review. Arch Intern Med. 2006;166(17):1805–1813. 

Milani, P., Merlini, G., & Palladini, G. (2018). Light Chain Amyloidosis. Mediterranean journal of hematology and infectious diseases, 10(1), e2018022. 

Said, G. Diabetic neuropathy—a review. Nat Rev Neurol 3, 331–340 (2007). 

Ziegler, D. (2008), Painful diabetic neuropathy: treatment and future aspects. Diabetes Metab. Res. Rev., 24: S52-S57. 

descargar

Detail description

Download

Request Information

WE GUIDE YOU

Fertility
Inherited diseases prevention
Healthy pregnancy

To see the accreditation certificate, associated technical annex and list of accredited tests, click on this link.

OUR SERVICES

Genetic testing solutions
For patients
How to send a sample?
User manual

ABOUT US

About Igenomix
Contact
Quality
Complaints
Work with us
Terms and conditions

FOLLOW IGENOMIX

  + 96 390 53 10
  Write us
  • Brazil
  • Canada
  • Europe
  • India
  • Italy
  • Japan
  • Korea
  • Latam
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
Country/Region

[2024] © Igenomix Privacy Page Quality policy Legal note Cookies policy

Request Information


  • Patient Journey
    • Before Pregnancy
    • IVF Process
    • Healthy pregnancy
    • After birth
  • Reproductive Health
    • Specialists
      • ERA
      • ERA insight Hub
      • ALICE
      • EMMA
      • EndomeTRIO
      • Infertility Panels
      • EMBRACE
      • PGT-A
      • PGT-A Plus
      • PGT-M
      • PGT-SR
      • CGT
      • NACE
      • Zenit
      • POC Portfolio
      • SAT
      • Newborn Screening
  • Diagnostics
  • About us
    • Igenomix Research
    • About Igenomix
    • Igenomix Worldwide
  • Academy
  • Blog
  • Country/Region
  • +34 96 390 53 10
  • Clinic Portal
  • Request Information